Immuneering
IMRX
34 hedge funds and large institutions have $56.9M invested in Immuneering in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
6% more funds holding
Funds holding: 32 → 34 (+2)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
1.32% less ownership
Funds ownership: 45.71% → 44.39% (-1.3%)
67% less capital invested
Capital invested by funds: $172M → $56.9M (-$116M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$399K |
| 2 |
Morgan Stanley
New York
|
+$298K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$289K |
| 4 |
State Street
Boston,
Massachusetts
|
+$221K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BSW
Buckingham Strategic Wealth
Clayton,
Missouri
|
-$2.87M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$962K |
| 3 |
BlackRock
New York
|
-$670K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$620K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$389K |
IMRX Hedge Fund Activity: Q4 2022 in Review
34 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q4 2022, worth a combined $56.9M — down 67% from $172M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMRX positions and 4 closed out — a net gain of 3 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $399K. The largest seller was Buckingham Strategic Wealth, exiting entirely with an estimated $2.87M sold.
- 34 institutional investors held Immuneering (IMRX) as of Q4 2022, up from 32 in Q3 2022.
- Funds reported $56.9M of Immuneering stock for Q4 2022, down 67% quarter-over-quarter.
- 7 funds opened new Immuneering positions in Q4 2022 and 4 closed out, a net change of +3 holders.
- The largest Immuneering buyer in Q4 2022 was Susquehanna International Group, an estimated $399K added.
- The largest Immuneering seller in Q4 2022 was Buckingham Strategic Wealth, an estimated $2.87M sold.
Based on aggregated 13F filings for Q4 2022.